EP1342090A1 - Vorrichtung und verfahren zur immunologischen analyse - Google Patents
Vorrichtung und verfahren zur immunologischen analyseInfo
- Publication number
- EP1342090A1 EP1342090A1 EP01999821A EP01999821A EP1342090A1 EP 1342090 A1 EP1342090 A1 EP 1342090A1 EP 01999821 A EP01999821 A EP 01999821A EP 01999821 A EP01999821 A EP 01999821A EP 1342090 A1 EP1342090 A1 EP 1342090A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- zone
- reaction
- state
- reagent
- analyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims description 30
- 238000003018 immunoassay Methods 0.000 title description 3
- 238000006243 chemical reaction Methods 0.000 claims abstract description 74
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 38
- 239000000126 substance Substances 0.000 claims abstract description 38
- 239000012491 analyte Substances 0.000 claims abstract description 34
- 239000000463 material Substances 0.000 claims abstract description 23
- 239000012530 fluid Substances 0.000 claims abstract description 14
- 238000004458 analytical method Methods 0.000 claims description 27
- 239000010410 layer Substances 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 230000005291 magnetic effect Effects 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 210000003743 erythrocyte Anatomy 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 239000012429 reaction media Substances 0.000 claims description 10
- 230000005298 paramagnetic effect Effects 0.000 claims description 9
- 238000011534 incubation Methods 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 7
- 230000001900 immune effect Effects 0.000 claims description 6
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 claims description 6
- 235000019818 tetrasodium diphosphate Nutrition 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000000536 complexating effect Effects 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 229940048086 sodium pyrophosphate Drugs 0.000 claims description 4
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 230000005670 electromagnetic radiation Effects 0.000 claims description 3
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 claims description 3
- 239000002356 single layer Substances 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 238000005497 microtitration Methods 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- 239000011888 foil Substances 0.000 claims 1
- 230000000704 physical effect Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 230000003100 immobilizing effect Effects 0.000 abstract 2
- 238000004166 bioassay Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 29
- 239000012620 biological material Substances 0.000 description 23
- 239000013060 biological fluid Substances 0.000 description 12
- 239000000872 buffer Substances 0.000 description 8
- 238000012546 transfer Methods 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical group O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000005294 ferromagnetic effect Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 101710186708 Agglutinin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108010089814 Plant Lectins Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000003726 plant lectin Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0016024 | 2000-12-08 | ||
| FR0016024A FR2817969B1 (fr) | 2000-12-08 | 2000-12-08 | Dispositif et procede d'analyse immunologique |
| PCT/FR2001/003888 WO2002046773A1 (fr) | 2000-12-08 | 2001-12-07 | Dispositif et procede d'analyse immunologique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1342090A1 true EP1342090A1 (de) | 2003-09-10 |
Family
ID=8857444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP01999821A Withdrawn EP1342090A1 (de) | 2000-12-08 | 2001-12-07 | Vorrichtung und verfahren zur immunologischen analyse |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20040063218A1 (de) |
| EP (1) | EP1342090A1 (de) |
| AU (1) | AU2002217217A1 (de) |
| FR (1) | FR2817969B1 (de) |
| WO (1) | WO2002046773A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2869996B1 (fr) * | 2004-05-05 | 2006-12-15 | Diagast Soc Par Actions Simpli | Utilisation de ferrofluides pour le phenotypage sanguin et applications derivees |
| US9488665B2 (en) * | 2005-09-13 | 2016-11-08 | Chrome Red Technologies, Llc | Magnetic particle tagged reagents and techniques |
| US20070059782A1 (en) * | 2005-09-13 | 2007-03-15 | Graham Henry A | Magnetic particle tagged blood bank reagents and techniques |
| WO2013181149A2 (en) * | 2012-05-29 | 2013-12-05 | Arryx, Inc. | Methods and devices for sample testing and evaluation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522923A (en) * | 1983-10-03 | 1985-06-11 | Genetic Diagnostics Corporation | Self-contained assay method and kit |
| US5013669A (en) * | 1988-06-01 | 1991-05-07 | Smithkline Diagnostics, Inc. | Mass producible biologically active solid phase devices |
| US5279936A (en) * | 1989-12-22 | 1994-01-18 | Syntex (U.S.A.) Inc. | Method of separation employing magnetic particles and second medium |
| FR2702050B1 (fr) * | 1993-02-26 | 1995-05-24 | Boy Inst Jacques | Procédé de groupage sanguin faisant appel à des réactions immunoenzymatiques. |
| NL9400777A (nl) * | 1994-05-10 | 1995-12-01 | Stichting Centraal Lab | Vaste-fase filtratiemethode voor antigeen- en antistofbepalingen in de bloedgroepserologie, en testkit. |
| US5536514A (en) * | 1995-05-11 | 1996-07-16 | The Nutrasweet Company | Carbohydrate/protein cream substitutes |
| US5756304A (en) * | 1995-07-14 | 1998-05-26 | Molecular Solutions | Screening of microorganisms for bioremediation |
| NL1003570C2 (nl) * | 1996-07-11 | 1998-01-15 | Stichting Centraal Lab | Methode voor antigeen- en antistofbepaling in de bloedgroepserologie. |
| AU6639400A (en) * | 1999-08-18 | 2001-03-13 | Microchips, Inc. | Thermally-activated microchip chemical delivery devices |
-
2000
- 2000-12-08 FR FR0016024A patent/FR2817969B1/fr not_active Expired - Fee Related
-
2001
- 2001-12-07 EP EP01999821A patent/EP1342090A1/de not_active Withdrawn
- 2001-12-07 AU AU2002217217A patent/AU2002217217A1/en not_active Abandoned
- 2001-12-07 WO PCT/FR2001/003888 patent/WO2002046773A1/fr not_active Application Discontinuation
- 2001-12-07 US US10/433,975 patent/US20040063218A1/en not_active Abandoned
Non-Patent Citations (2)
| Title |
|---|
| None * |
| See also references of WO0246773A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2817969B1 (fr) | 2003-02-28 |
| FR2817969A1 (fr) | 2002-06-14 |
| WO2002046773A1 (fr) | 2002-06-13 |
| US20040063218A1 (en) | 2004-04-01 |
| AU2002217217A1 (en) | 2002-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2892820A1 (fr) | Procede magnetique d'immunodiagnostic pour la mise en evidence de complexe anticorps/antigene, en particulier de groupe sanguin | |
| FR2963108A1 (fr) | Procede magnetique d'immunodiagnostic et kit pour la mise en evidence de complexe anticorps/antigene de groupe/phenotype sanguin | |
| EP1745290B1 (de) | Verwendung von ferrofluiden zur bestimmung des blutgruppenphenotyps und abgeleitete anwendungen | |
| JPH11246593A6 (ja) | 蛋白質および同類品の保護 | |
| EP1342088A1 (de) | Verfahren für die magnetisierung der chemischen und biologischen markierungen | |
| WO1989010564A1 (fr) | Dispositif et procede pour la determination qualitative et quantitative rapide de la presence d'un ligand reactif dans un fluide | |
| EP1082451B1 (de) | Verfahren zur bestimmung des beta-lactam nukleus enthaltenden antibiotikums | |
| EP0311492A2 (de) | Immuntestsatz und -verfahren für ganze Zellen | |
| WO2002045858A2 (fr) | Barriere de separation temporaire, recipient la comprenant et procede de mise en oeuvre d'un test dans ce recipient | |
| EP1342090A1 (de) | Vorrichtung und verfahren zur immunologischen analyse | |
| FR2486657A1 (fr) | Procede de detection et de dosage d'une substance biologique par erythroadsorption | |
| FR2615621A1 (fr) | Composes et procedes permettant une agglutination reversible, et kits analytiques contenant lesdits composes | |
| EP0542655B1 (de) | Vorrichtung zur Trennung und Bestimmung der Erythrozyt-Agglutinate in einem Schritt | |
| WO1990007118A2 (fr) | Anticorps polymerises, diriges contre des immunoglobulines - leur utilisation dans des tests de diagnostic | |
| EP0008245A1 (de) | Physisch-biochemisches System zum Nachweisen, Dosieren und Isolieren von Substanzen mit antigenischer Aktivität | |
| EP0594506B1 (de) | Immunodiagnostisches Verfahren mit Hilfe einer porösen Affinitätsmatrix mit sensibilisierten Partikeln und Vorrichtung dafür | |
| EP0544578B1 (de) | Satz zur schnellen Aufzählung von Granulocyten und Verfahren das diesen Satz verwendet | |
| FR2673472A1 (fr) | Procede pour la mise en evidence d'agglutinats eythrocytaires. | |
| WO2002016942A1 (fr) | Procede d'analyse immunologique par reaction d'adherence | |
| FR2790093A1 (fr) | Procede d'analyse immunologique par reaction d'adherence | |
| EP0598014B1 (de) | Verwendung von Atelokollagen als Festträger für die Fixierung eines spezifischen Fängers | |
| WO1995006252A1 (fr) | Procede d'identification d'une substance immunologique au moyen d'un systeme multimembranaire | |
| FR2581194A1 (fr) | Dispositif pour l'analyse d'un liquide biologique. | |
| FR2685956A1 (fr) | Procede et dispositif de test par agglutination de particules. | |
| EP0882788B1 (de) | Verfahren zur Trennung von Blutbestandteilen oder aus Blutplätchen Mikropartikel aus einem diese enthaltenten Muster |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20030707 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: VINZIA, CHRISTOPHE Inventor name: OVLAQUE, GERARD Inventor name: MENARD, SANDIE Inventor name: GAILLARD, LAETITIA Inventor name: CHEVALEYRE, JEAN, ALAIN Inventor name: BETREMIEUX, CHRISTINE Inventor name: BUFFIERE, FREDERIC |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20070424 |